Clinical Trial

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Study acronym: CAMCO2
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2023 (before its estimated February 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-04-30; most recent amendment 2023-12-05.
Status change: Not Yet Recruiting → Recruiting 2023-12-05
Trial Details
NCT Number NCT05360277
Lead Sponsor Yanhong Deng
Conditions Metastatic Colorectal Cancer，NED
Enrollment 52 participants
Start Date 2023-08-22
Primary Completion 2025-02-28 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2023-12-12